These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 39334845)

  • 1. The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid.
    Song Y; Wu Y; Ding F; Li S; Shen Y; Yang B; Tang X; Ren L; Deng L; Jin X; Yan Y
    Biomolecules; 2024 Aug; 14(9):. PubMed ID: 39334845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
    Sandercock PA; Counsell C; Tseng MC
    Cochrane Database Syst Rev; 2008 Jul; (3):CD000119. PubMed ID: 18646059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of protein C activation by histones, platelet factor 4, and heparinoids: new insights into activated protein C formation.
    Kowalska MA; Zhao G; Zhai L; David G; Marcus S; Krishnaswamy S; Poncz M
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):120-6. PubMed ID: 24177324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
    Sandercock PA; Leong TS
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD000119. PubMed ID: 28374884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin: the cheap alternative for immunomodulation in sepsis?
    Robertson MS
    Crit Care Resusc; 2006 Sep; 8(3):235-8. PubMed ID: 16930112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
    Sandercock P; Counsell C; Stobbs SL
    Cochrane Database Syst Rev; 2005 Apr; (2):CD000119. PubMed ID: 15846600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparinoids Danaparoid and Sulodexide as clinically used drugs.
    Dou H; Song A; Jia S; Zhang L
    Prog Mol Biol Transl Sci; 2019; 163():55-74. PubMed ID: 31030761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparinoids: structure, biological activities and therapeutic applications.
    Gunay NS; Linhardt RJ
    Planta Med; 1999 May; 65(4):301-6. PubMed ID: 10364832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heparin, low molecular weight heparin, heparinoid, and antithrombin III therapy of disseminated intravascular coagulation].
    Nakagawa M
    Nihon Rinsho; 1993 Jan; 51(1):87-92. PubMed ID: 7679453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
    Counsell C; Sandercock P
    Cochrane Database Syst Rev; 2000; (2):CD000119. PubMed ID: 10796301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond-A review of 31 years clinical experiences in China.
    Shan M; Feng N; Zhang L
    Prog Mol Biol Transl Sci; 2019; 163():75-93. PubMed ID: 31030762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypocoagulation state in severe systemic inflammatory response syndrome/sepsis is consistent with endogenous heparinoid effect as detected by thromboelastography.
    Durila M; Bures J; Pelichovská M; Cvavhovec K
    Anaesth Intensive Care; 2011 May; 39(3):508-9. PubMed ID: 21675080
    [No Abstract]   [Full Text] [Related]  

  • 13. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
    Counsell C; Sandercock P
    Cochrane Database Syst Rev; 2001; (4):CD000119. PubMed ID: 11687069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of heparin fractions: issues and answers.
    Messmore HL
    Crit Rev Clin Lab Sci; 1986; 23(2):77-94. PubMed ID: 2419035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function.
    Mikhailidis DP; Barradas MA; Mikhailidis AM; Magnani H; Dandona P
    Br J Clin Pharmacol; 1984 Jan; 17(1):43-8. PubMed ID: 6197984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unfractionated heparin dosing requirements in the presence of inflammation during the first six months of life.
    Heizer JW; Schardt TQ; Murphy ME; Branchford BR
    Thromb Res; 2019 May; 177():17-22. PubMed ID: 30844684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and biological activity of heparinoid.
    Kumar N; Bentolila A; Domb AJ
    Mini Rev Med Chem; 2005 May; 5(5):441-7. PubMed ID: 15892686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical use of heparin-heparinoid-mixtures].
    Hörder MH; Stier WD; Brunswig D
    Arzneimittelforschung; 1969 Nov; 19(11):1873-6. PubMed ID: 4190000
    [No Abstract]   [Full Text] [Related]  

  • 19. Heparin, non-heparin glycosaminoglycans, and heparinoids: an overview of their application in atherosclerosis.
    Engelberg H
    Semin Thromb Hemost; 1991; 17 Suppl 1():5-8. PubMed ID: 1712511
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging therapeutic strategies targeting extracellular histones for critical and inflammatory diseases: an updated narrative review.
    Yang T; Peng J; Zhang Z; Chen Y; Liu Z; Jiang L; Jin L; Han M; Su B; Li Y
    Front Immunol; 2024; 15():1438984. PubMed ID: 39206200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.